NYSE:MYOV (UK) Also trade in: Germany

Myovant Sciences Ltd

$ 9.31 0 (0%)
Volume: 114,222 Avg Vol (1m): 376,772
Market Cap $: 834.37 Mil Enterprise Value $: 777.68 Mil
P/E (TTM): 0.00 P/B: 150.18
Earnings Power Value 0
Net Current Asset Value -0.03
Tangible Book 0.06
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 1.57
Cash-To-Debt ranked lower than
66.33% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
MYOV: 1.57
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 1.57, Med: 2.49, Max: 10000
Current: 1.57
1.57
10000
Debt-to-Equity 22.93
Debt-to-Equity ranked lower than
77.40% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
MYOV: 22.93
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 1.16, Med: 12.04, Max: 22.93
Current: 22.93
1.16
22.93
Debt-to-EBITDA -0.38
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
MYOV: -0.38
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.38, Med: -0.34, Max: -0.31
Current: -0.38
-0.38
-0.31
Piotroski F-Score 1
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.48
DISTRESS
GREY
SAFE

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -613.19
ROE ranked lower than
88.88% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
MYOV: -613.19
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -1300.67, Med: -140.1, Max: -100.2
Current: -613.19
-1300.67
-100.2
ROA % -167.56
ROA ranked lower than
90.59% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
MYOV: -167.56
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -187.31, Med: -94.13, Max: -90.07
Current: -167.56
-187.31
-90.07
ROC (Joel Greenblatt) % -16750.38
ROC (Joel Greenblatt) ranked lower than
88.42% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
MYOV: -16750.38
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -18435.76, Med: -15804.67, Max: -12941.35
Current: -16750.38
-18435.76
-12941.35

» MYOV's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:MYOV

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 0    SIC : 0
Compare XPAR:ALCLS NAS:GTHX NAS:ITCI ASX:SRX NAS:DVAX NAS:ARMO NAS:TGTX XPAR:DBV NAS:ASMB NAS:CTMX NAS:WVE NYSE:CO NAS:APLS TSXV:CRON OSTO:HMED SHSE:600200 NAS:RVNC NAS:ADAP NAS:ACOR NAS:BOLD
Traded in other countries 71M.Germany
Address 11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its product candidate is relugolix.

Ratios

Current vs industry vs history
PB Ratio 150.18
PB Ratio ranked lower than
94.07% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
MYOV: 150.18
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 200.48
Current: 150.18
0
200.48
EV-to-EBIT -2.94
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
MYOV: -2.94
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -21.98, Med: 0, Max: 0
Current: -2.94
-21.98
0
EV-to-EBITDA -2.95
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
MYOV: -2.95
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -21.98, Med: 0, Max: 0
Current: -2.95
-21.98
0
Current Ratio 2.32
Current Ratio ranked lower than
62.85% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
MYOV: 2.32
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.32, Med: 3.09, Max: 10.04
Current: 2.32
2.32
10.04
Quick Ratio 2.32
Quick Ratio ranked lower than
60.34% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
MYOV: 2.32
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 2.32, Med: 3.09, Max: 10.04
Current: 2.32
2.32
10.04

Dividend & Buy Back

Current vs industry vs history

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 155.17
Price-to-Tangible-Book ranked lower than
90.72% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
MYOV: 155.17
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 4.24, Med: 34.36, Max: 367.23
Current: 155.17
4.24
367.23
Earnings Yield (Joel Greenblatt) % -34.02
Earnings Yield (Greenblatt) ranked lower than
61.52% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
MYOV: -34.02
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -46.78, Med: 0, Max: 0
Current: -34.02
-46.78
0

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 1
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N